The Clinical Research Development (Core B), is under the direction of Dr. Allen D. Roses, Program Director and Principal Investigator for the Joseph and Kathleen Bryan Alzheimer's Disease Research Center. The Core is divided into five components that directly contribute to research efforts of the Center and enable the Center to functionally integrate the clinical, research, education and resource components. Section 1, the Clinical Unit consists of the Memory Disorders Clinic which serves to provide the clinical diagnoses, care and clinical research development and ascertainment for the genetic studies. Section 2, the Neuropsychology Unit, Kathleen A. Welsh, Section Leader, provides the expertise for neuropsychological evaluations of MDC patients, clinical research protocols and affected and at-risk individuals in Alzheimer's disease families. Section 3, the Data Management Unit, Deborah V. Dawson, Section Leader, provides each component of the Bryan ADRC with statistical expertise and comprehensive support in study design, data collection and management, and statistical analysis. Section 4, the Rapid Autopsy Protocol, provides a unique source of patient and clinically tested control tissue for research studies at Duke University and other institutions on a national and international level. The final part, Section 5, Faculty development, is designed to train and focus opportunities for academic faculty development as a transition to a five-year research commitment through the National Institute on Aging's Clinical Investigator Award.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005128-09
Application #
3790032
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Petyuk, Vladislav A; Chang, Rui; Ramirez-Restrepo, Manuel et al. (2018) The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target. Brain 141:2721-2739
Sims, Rebecca (see original citation for additional authors) (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49:1373-1384
Jun, Gyungah R; Chung, Jaeyoon; Mez, Jesse et al. (2017) Transethnic genome-wide scan identifies novel Alzheimer's disease loci. Alzheimers Dement 13:727-738
Karch, Celeste M; Ezerskiy, Lubov A; Bertelsen, Sarah et al. (2016) Alzheimer's Disease Risk Polymorphisms Regulate Gene Expression in the ZCWPW1 and the CELF1 Loci. PLoS One 11:e0148717
Mez, Jesse; Mukherjee, Shubhabrata; Thornton, Timothy et al. (2016) The executive prominent/memory prominent spectrum in Alzheimer's disease is highly heritable. Neurobiol Aging 41:115-121
Ridge, Perry G; Hoyt, Kaitlyn B; Boehme, Kevin et al. (2016) Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiol Aging 41:200.e13-200.e20
Hohman, Timothy J; Bush, William S; Jiang, Lan et al. (2016) Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics Consortium. Neurobiol Aging 38:141-150
Jun, G; Ibrahim-Verbaas, C A; Vronskaya, M et al. (2016) A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry 21:108-17
Hohman, Timothy J; Cooke-Bailey, Jessica N; Reitz, Christiane et al. (2016) Global and local ancestry in African-Americans: Implications for Alzheimer's disease risk. Alzheimers Dement 12:233-43
Ghani, Mahdi; Reitz, Christiane; Cheng, Rong et al. (2015) Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals. JAMA Neurol 72:1313-23

Showing the most recent 10 out of 97 publications